Processing

Please wait...

Settings

Settings

Goto Application

1. WO2014127463 - METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION

Publication Number WO/2014/127463
Publication Date 28.08.2014
International Application No. PCT/CA2014/000139
International Filing Date 20.02.2014
IPC
C12Q 1/68 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
G01N 33/48 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
G01N 33/53 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
G06F 19/20 2011.1
GPHYSICS
06COMPUTING; CALCULATING OR COUNTING
FELECTRIC DIGITAL DATA PROCESSING
19Digital computing or data processing equipment or methods, specially adapted for specific applications
10Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
20for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation
CPC
C12Q 1/6883
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
C12Q 2600/112
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
112Disease subtyping, staging or classification
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
G01N 2333/4727
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4727Calcium binding proteins, e.g. calmodulin
G01N 2333/5412
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
52Assays involving cytokines
54Interleukins [IL]
5412IL-6
G01N 2333/5428
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
52Assays involving cytokines
54Interleukins [IL]
5428IL-10
Applicants
  • UNIVERSITY HEALTH NETWORK [CA]/[CA]
Inventors
  • KESHAVJEE, Shaf
  • LIU, Mingyao
  • CYPEL, Marcelo
Agents
  • BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.
Priority Data
61/766,89420.02.2013US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF MEASURING IL-6 EXPRESSION TO DETERMINE RISK OF CHRONIC ALLOGRAFT LING DYSFUNCTION
(FR) MÉTHODES DE MESURE DE L'EXPRESSION D'IL-6 POUR DÉTERMINER UN RISQUE DE DYSFONCTIONNEMENT CHRONIQUE DE GREFFE ALLOGÉNIQUE DE POUMON
Abstract
(EN) Methods for assaying a donor lung for chronic allograft lung dysfunction (CLAD) optionally bronchiolitis obliterans syndrome (BOS) subtype or restrictive allograft syndrome (RAS) subtype of CLAD or risk of developing BOS subtype or RAS subtype CLAD post-transplant, the method comprising: a. measuring a normalized expression level of an RNA transcript of IL-6 or an expression product thereof in a sample of the donor lung pre-transplant or a normalized expression level of one or more S100 protein, optionally S100A8 and/or S100A9, polypeptide expression product in a sample from the donor lung post-transplant; b. assessing the likelihood of the donor lung developing BOS subtype CLAD or RAS subtype CLAD post-transplant based on said IL-6, S100, optionally S100A8 and/or S100A9, expression level wherein IL-6 expression level is positively correlated with an increased likelihood of developing BOS post-transplant, S100A8 expression level is positively correlated with having or having an increased likelihood of developing RAS and/or BOS subtype CLAD, and S100A9 is positively correlated with having and having an increased likelihood of developing RAS subtype CLAD.
(FR) L'invention concerne des méthodes pour évaluer un poumon donneur pour déterminer un dysfonctionnement chronique de greffe allogénique de poumon (CALD), éventuellement le sous-type du syndrome de la bronchiolite oblitérante (BOS) ou le sous-type du syndrome restrictif (RAS) de CALD ou le risque de développer le sous-type BOS ou le sous-type RAS de CALD après la transplantation, le procédé comprenant : a. la mesure d'un niveau d'expression normalisé d'un transcrit d'ARN d'IL-6 ou un produit d'expression de celui-ci dans un échantillon du poumon donneur avant la transplantation ou d'un niveau d'expression normalisé d'une ou de plusieurs protéines S100, éventuellement S100A8 et/ou S100A9, d'un produit d'expression polypeptidique dans un échantillon du poumon donneur après la transplantation; b. l'évaluation de la probabilité que le poumon donneur développe un CALD de sous-type BOS ou un CALD de sous-type RAS après la transplantation à partir dudit niveau d'expression d'IL-6, S100, éventuellement de S100A8 et/ou ou de S100A9, le niveau d'expression d'IL-6 étant positivement corrélé avec le développement ou une probabilité accrue de développer un CALD de sous-type RAS et/ou BOS, et S100A9 étant positivement corrélé avec le développement ou une probabilité accrue de développer un CALD de sous-type RAS.
Related patent documents
Latest bibliographic data on file with the International Bureau